ReviewPharmaceuticals (Basel, Switzerland)2024
Ischemic Optic Neuropathy: A Review of Current and Potential Future Pharmacotherapies.
Review in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION) and High-Risk Cardiovascular Events.Life (Basel, Switzerland) · 2026Article
- Baseline retinal nerve fiber layer thickness as a predictive biomarker for endoscopic optic canal decompression in NAION: towards a precision medicine approach.Journal of translational medicine · 2026Article
- Longitudinal assessment of macular structure-function and vasculature-function correlations across different stages of nonarteritic anterior ischemic optic neuropathy.Quantitative imaging in medicine and surgery · 2026Article
- Acute Ischemic Stroke in Non-Arteritic Anterior Ischemic Optic Neuropathy.Diagnostics (Basel, Switzerland) · 2025Article
- Citicoline May Effectively Reduce Hard Exudates in Diabetic Retinopathy.Biomedicines · 2025Article
- A 54-year-old male with posterior ischemic optic neuropathy misdiagnosed as ophthalmic artery occlusion.BMC ophthalmology · 2025Article
- High-resolution MRI features of nonarteritic anterior ischemic optic neuropathy: a case series.International journal of ophthalmology · 2025Article
- Public health implications of delayed diagnosis and treatment of optic neuritis in low-resource settings: a retrospective study of visual recovery outcomes.Frontiers in ophthalmology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of arteritic anterior ischemic optic neuropathy (AAION), non-arteritic ischemic optic neuropathy (NAAION), and posterior ischemic optic neuropathy (PION) is a topic of ongoing research with mixed evidence on some pharmacotherapies and a need for more consensus. This manuscript provides an overview of these conditions' current, potential future, and attempted pharmacotherapies. AAION's current treatment regimen consists of high-dose steroids, with methotrexate, tocilizumab, and abatacept, being the most viable steroid-sparing therapy candidates. As for NAAION, the treatments being tried are vast, with mixed evidence supporting each modality. Similarly, despite the various treatment options explored, there still needs to be a universally effective therapy for PION. More research is needed to formulate an agreed-upon treatment regimen for these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.